Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.
For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.
The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.
Hamilton et al. perform proteogenomic analyses to discover high-confidence candidate immunotherapeutic targets in neuroblastoma. Delta-like canonical notch ligand 1 (DLK1) is prioritized and validated. A DLK1-directed…
Cancer is a major and worsening global challenge. It is the leading cause of death and disease burden in most countries worldwide, with large inequalities…
Patients and caregivers will find support and camaraderie at Together Facing Lung Cancer, a free educational workshop. The program will feature a panel of Fox…
An abstract is unavailable.
The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.
Andrew Chapman and Kuang-Yi Wen of Thomas Jefferson University were named scientific awardees for their work in geriatric oncology research.
Health care workers @OSUWexMed have a unique support staff in the form of four-legged therapy dogs from #BuckeyePaws, who provide therapeutic visits to health care…